Osimertinib-Induced Cardiomyopathy

Shruti R Patel; Sherry-Ann N Brown; Jilan E Kubusek; Aaron S Mansfield; Narjust Duma

doi:10.1016/j.jaccas.2019.12.038

Osimertinib-Induced Cardiomyopathy

JACC Case Rep. 2020 Apr 1;2(4):641-645. doi: 10.1016/j.jaccas.2019.12.038. eCollection 2020 Apr.

Authors

Shruti R Patel¹, Sherry-Ann N Brown², Jilan E Kubusek³, Aaron S Mansfield³, Narjust Duma⁴

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
³ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
⁴ Division of Medical Oncology, University of Wisconsin, Madison, Wisconsin.

Abstract

Osimertinib is the preferred treatment in patients with metastatic non-small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.).

Keywords: CHF, congestive heart failure; EF, ejection fraction; EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; TKI, tyrosine kinase inhibitor; cardio-oncology; cardiotoxicity; heart failure; osimertinib; reduced ejection fraction.

Publication types

Case Reports